Phytotherapy benign prostatic hyperplasia in persons with diabetes mellitus
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to evaluate the possibility of the long-term monotherapy with the Gentos Forte® in benign prostatic hyperplasia (BPH) of the 1-th degree on the background of diabetes mellitus (DM) of the 2nd type.
Patients and methods. The advisory polyclinic SI «Institute of Urology of NAMS of Ukraine» was observed 95 men. The first group (n=31) consisted of persons with symptoms of BPH 1 tbsp. against the background of verified diabetes type II (mean age 54,8±1,3 years) who received monotherapy Gentos Forte® (Bittner Pharma). Group II (n=34) comprised patients with the same condition (mean age 55,6±1,0 years) treated with monotherapy Cucurbita pepo globulin 600 mg/day. History of the disease duration on diabetes type II averaged 8,1±0,7 years; for BPH – an average of 6,3±0,5 years. In the III group included 30 patients with BPH of age who are not receiving any treatment in tech 1 year. Conducts clinical (questioning by IPSS, QoL, and compliance to the International Index of Erectile Function) and additional (transrectal ultrasound of the prostate research) study of pre– and after 3 months from the beginning of the observation.
Results. A clinical (survey on IPSS, QoL, compliance and the International index of erectile function) and additional (transrectal ultrasound of the prostate) researches were before and after 3 months from the beginning of observation. The results of the study indicate that monotherapy with Gentos Forte® is a reliable alternative in individuals with a clinical Association of BPH and DM, and the effectiveness of this therapy may depend on the severity of the process and the duration of the assigned therapy.
Conclusions. 1. Clinic of benign prostatic hyperplasia in patients with diabetes type 2 diabetes, is characterized by severe symptoms of lower urinary tract symptoms, with a decrease in erectile function and requires a conservative treatment in view of the pathogenesis of the disease.
2. Monotherapy Gentos Forte® carried out within 90 day, helped to reduce the manifestations of lower urinary tract symptoms by 33.4% (in the II group – 14.9%), improving the quality of life index of 44.7% (in the II group – 16.0%), as well as a decrease in prostate size in 54.8% of subjects at 14,7±0,4% cm3 (p <0.05).
3. Application Gentos Forte® at 58.6% (p<0.05) persons of the I group promoted the optimization of Erectile Function (IIEF questionnaire according to) in the period after the 90 monotherapy.
4. Monotherapy in patients I-th group was characterized by a high compliance (other than according to the physician survey – 93.5%, patient – 90.3%) and lack of adverse events in 100% of cases.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Waram J.H., Krolewski A.S. Epidemiology of diabetes mellitus // Joslin’s Diabetes mellitus. – Philadelphia: Lippincott Williams & Wilkins, 2006. – P. 115–144.
Основні показники діяльності ендокринол. служби України за 2000–2006 роки // Інститут ендокринол. та обміну речовин ім. В.П. Комісаренка. – К., 2000–2006. – 33 с.
Горпинченко И.И., Имшинецкая Л.П. Гормонотерапия половых расстройств у мужчин и другие методы медикаментозного лечения. – К.: Комполис, 2001. – 220 с.
Комаревцев В.Н., Спиридоненко В.В., Пепенин В.Р., Беличенко О.В., Пепенин С.В., Луцкий В.И. Фитотерапия и оптимизация показателей качества жизни и данных эякулята у лиц с хроническим простатитом // Здоровье мужчины. – 2001. – No 3 (38). – С. 34–39.
Горпинченко І.І., Гурженко Ю.М., Спиридоненко В.В. Сучасні дані про вплив хронічного запалення в патогенезі доброякісної гіперплазії передміхурової залози і раку передміхурової залози // Здоровье мужчины. – 2014. – No 4. – С. 91–94.
Сайдакова Н.О., Старцева Л.М., Кравчук Н.Г. Основні показники уролог. допомоги в Україні за 2010-2011 роки: відомче видання / ДУ «Інститут урології НАМУ», Центр мед. стат. К.: Поліум, 2011. – 199 с.
Древаль А.В., Мясникова И.В., Редькин Ю.А. Регистр СД, как базис контроля лечебно-профилак. помощи больным // Проблемы эндокринологии. – 1999. – Т. 45, No 5. – С. 42–48.
Бова Ф.С. Уролитаз и сахарный диабет. Особенности диагностики и лечения: Автореф. дис. ... канд. мед. наук: 14.01.23 – урология; 14.01.02 – эндокринология // Ф.С. Бова. – М., 2010. – 21 с.
Дзюрак В.С., Гайсенюк Ф.З. Патогенез, класифікація та лікування коралоподібного нефролітіазу // Клін. хірургія. – 1999. – No 1. – С. 48–49.
Griffin M.D., Bergstralhn E.J., Larson T.S. Renal papillary necrosis – a sixteen-year clinical experience // J. Amer. Soc. Nephrol. – 1995. – V. 6. – P. 248–56.
Балаболкин М.И. Диабетология. – М.: Медицина, 2000. – С. 10–11.
Ефимов А.С. Патогенез и лечение хронических осложнений сахарного диабета // Ендокрінологія. – 2007. – No 12. – С. 73–74.
Дедов И.И., Курбатов Д.Г. и соавт. Урологические и андрологические заболевания при сахарном диабете // Урология. – 2009. – No 4. – С. 74–79.
Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complement Ther Med. 2013 Jun;21 (3):172–9.
Scheider T., Rubben H. Bennesseltrockenextrakt (Bazoton-uno) in der Langzeittherapie des benignen Prostatasyndroms (BPS). Ergebnisse einer ... //Urologe A. 2004. Mar; 43 (3): P. 302–306.
Kessopoulou E., Russel J.M., Powers H.J. et al. A double blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility //Fertil. Steril. 2007. – Vol. 64. – P. 825–831.
Safarinejad M.R. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double rind, placebo-controlled, crossover study // J. Herb. Pharmacoter., 2005; V. 5 (4). – P. 1 – 11 (lev. 1b).
Горпинченко И.И., Гурженко Ю.Н., Клименко П.М., Шуляк А.В., Спиридоненко В.В. Исследование Проспект 2 (ПРОСтамол: ПЕрспективы Комбинированной Терапии) при ДГПЖ // Здоровье мужчины. – 2012. – No 1. – С. 56–60.
De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. – V. 91. – P. 459–477.
Ficarra V, Rossanese M, Zazzara M et. al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy//Curr Urol Rep. 2014. Dec;15(12): P. 463.
Forray C., Bard J.A., Wetzel J.M. et al. The б1(adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human б1с subtype. Mol. Pharmacol. 1994; 45 (4):703–708.
Lowe F., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia// Curr. Opin. Urol. – 2002; Vol. 12; P. 15.
Bostanci Y., Kazzazi A., Momtahen S., Laze J., Djavan В. Correlation between benign prostatic hyperplasia and inflammation // BENIGN PROSTATIC HYPERPLASIA. 2013 – Vol. 23 (1). – Р. 5–10.
Di Silverio F., Bosman C., Salvatori M. et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) // Eur. Urol. – 2005. – V. 47 – P. 72–79.
Berges R.R., Pientka L., Hufner K. et al. Male lower urinary tract symptoms and related health care seeking in Germany// Eur. Urology. – 2001. – Vol. 39. – P. 682.
Vela(Navarrete R., Escribano-Burgos M., Farré A.L et al. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia // J Urol.– 2005 Feb; V. 173 (2). – P. 507–10.
Zhou T, Yang Y, Zhang H et al. Serenoa Repens Induces Growth Arrest, Apoptosis and Inactivation of STAT3 Signaling in Human Glioma Cells //Technol Cancer Res Treat. – 2014 Jun V. 16. – P. 12–16.
Dennis L., Lynch C.F., Tornes J.C. Epidemiologic association between prostatitis and prostate cancer // Urology. – 2002. – V. 60. – P. 78–83.
Abdelwahab S.I., Mohan S., Mohamed Elhassan M. et al. Antiapoptotic and Antioxidant Properties of Orthosiphon stamineus Benth (Cat’s Whiskers): Intervention in the Bcl-2-Mediated Apoptotic Pathway. Evid Based Complement Alternat Med. 2011; 2011:156765.
Mohamed E.A., Ahmad M., Ang L.F., Asmawi M.Z., Yam M.F. Evaluation of б-Glucosidase Inhibitory Effect of 50% Ethanolic Standardized Extract of Orthosiphon stamineus Benth in Normal and Streptozotocin-Induced Diabetic Rats. Evid Based Complement Alternat Med. 2015; 2015:754931.
Gao S., Chen W., Peng Z. et al. Urinary metabonomics elucidate the therapeutic mechanism of Orthosiphon stamineus in mouse crystal-induced kidney injury. J Ethnopharmacol. 2015 May 26; 166:323–32.
Al-Suede F.S., Khadeer Ahamed M.B., Abdul Majid A.S. et al. Optimization of Cat’s Whiskers Tea (Orthosiphon stamineus) Using Supercritical Carbon Dioxide and Selective Chemotherapeutic
Potential against Prostate Cancer Cells. Evid Based Complement Alternat Med. 2014; 2014:396016.
Pagano E., Laudato M., Griffo M., Capasso R. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res. 2014 Jul;28(7):949–55.
Tomar P.P., Nikhil K., Singh A. et al. Characterization of anticancer, Dnase and antifungal activity of pumpkin 2S albumin. Biochem Biophys. Res. Commun. 2014 Jun 13;448(4):349–54.
Эффективность и безопасность препарата Простаплант®форте при LUTS, обусловленных доброкачественной гиперплазией предстательной железы (Обзор клинических исследований) // Здоровье мужчины, 2006. – No3. – С. 110 – 113.
Berges R.R., Pientka L., Hufner K. et al. Male lower urinary tract symptoms and related health care seeking in Germany. Eur. Urology. 2001. – Vol. 39. – P. 682.
Lowe F., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr. Opin. Urol. 2002; Vol. 12. – P. 15.
Sokelend J., Schlafke S. Долгосрочные эффекты ПРО 160/120 (Простаплант®форте) у пациентов с симптоматической доброкачественной гиперплазией предстательной
железы // Здоровье мужчины. – 2007. – No 4. – С. 68–69.
Неймарк С.А., Алиев Р.Т. Значение исследования энзимов спермальной плазмы в патогенезе относительного мужского бесплодия // Урология. – 2000. – No 3. – С. 34–37.
Кудрин А.В,, Скальный А.В., Жаворонков А.А. и др. Иммунофармакология микроэлементов. – М.: Из-во КМК. – 2000. – 537 с.
Горпинченко И.И., Гурженко Ю.М., Спиридоненко В.В. Можливості впливу фітокорекції на пригнічення процесів доброякісної гіперплазії передміхурової залози в осіб із супутніми хронічними запальними захворюваннями передміхурової залози // Здоровье мужчины. – 2016. – No 1 (56). – С. 121–126.
